Emmaus Life Sciences Performance
| EMMADelisted Stock | USD 0.26 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.41, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Emmaus Life are expected to decrease at a much lower rate. During the bear market, Emmaus Life is likely to outperform the market. Emmaus Life Sciences right now shows a risk of 0.0%. Please confirm Emmaus Life Sciences total risk alpha, downside variance, day median price, as well as the relationship between the maximum drawdown and skewness , to decide if Emmaus Life Sciences will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Emmaus Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, Emmaus Life is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 2.5 M | |
| Total Cashflows From Investing Activities | -6.4 M |
Emmaus |
Emmaus Life Relative Risk vs. Return Landscape
If you would invest 26.00 in Emmaus Life Sciences on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Emmaus Life Sciences or generate 0.0% return on investment over 90 days. Emmaus Life Sciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Emmaus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Emmaus Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Emmaus Life's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Emmaus Life Sciences, and traders can use it to determine the average amount a Emmaus Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EMMA |
Based on monthly moving average Emmaus Life is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Emmaus Life by adding Emmaus Life to a well-diversified portfolio.
Emmaus Life Fundamentals Growth
Emmaus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Emmaus Life, and Emmaus Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Emmaus OTC Stock performance.
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.65) % | ||||
| Current Valuation | 49.41 M | ||||
| Shares Outstanding | 49.56 M | ||||
| Price To Earning | (1.60) X | ||||
| Price To Sales | 1.06 X | ||||
| Revenue | 20.61 M | ||||
| EBITDA | (12.76 M) | ||||
| Cash And Equivalents | 982 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 4.65 M | ||||
| Debt To Equity | (0.04) % | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (1.25 M) | ||||
| Earnings Per Share | (0.18) X | ||||
| Total Asset | 56.73 M | ||||
| Retained Earnings | (82.78 M) | ||||
| Current Asset | 9.19 M | ||||
| Current Liabilities | 7.25 M | ||||
About Emmaus Life Performance
By analyzing Emmaus Life's fundamental ratios, stakeholders can gain valuable insights into Emmaus Life's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Emmaus Life has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Emmaus Life has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California. Emmaus Life operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 58 people.Things to note about Emmaus Life Sciences performance evaluation
Checking the ongoing alerts about Emmaus Life for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Emmaus Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Emmaus Life Sciences is not yet fully synchronised with the market data | |
| Emmaus Life Sciences has some characteristics of a very speculative penny stock | |
| Emmaus Life Sciences has a very high chance of going through financial distress in the upcoming years | |
| Emmaus Life Sciences currently holds 4.65 M in liabilities. Emmaus Life Sciences has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Emmaus Life until it has trouble settling it off, either with new capital or with free cash flow. So, Emmaus Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Emmaus Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Emmaus to invest in growth at high rates of return. When we think about Emmaus Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 20.61 M. Net Loss for the year was (15.95 M) with profit before overhead, payroll, taxes, and interest of 17.3 M. | |
| Emmaus Life Sciences currently holds about 982 K in cash with (1.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 39.0% of the company shares are held by company insiders |
- Analyzing Emmaus Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Emmaus Life's stock is overvalued or undervalued compared to its peers.
- Examining Emmaus Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Emmaus Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Emmaus Life's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Emmaus Life's otc stock. These opinions can provide insight into Emmaus Life's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Emmaus OTC Stock
If you are still planning to invest in Emmaus Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Emmaus Life's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |